AbbVie’s Rinvoq Shines In First Of Three Eczema Pivotal Studies

The JAK1 inhibitor showed skin clearance and itch reduction in first of three Phase III trials. Analysts say blockbuster atopic dermatitis indication is possible if data hold up in ongoing studies.